LAFRANCOL

Quality and Innovative Pharmaceutical Products Since 1911

Company Overview
Founded in 1911 Successfully distributed French pharmaceutical products in Latin America - bulk imports, packaging and distribution. In 1945, Lafrancol opens its first plant becoming the first manufacturer of pharmaceuticals in Colombia Continuous modernization has resulted in one of the most modern plants in Latin America. Today, Lafrancol is the #1 Pharmaceutical Company in Colombia

MARKET POSITION

Lafrancol: Premiere Enterprise

A commitment to providing quality products has established Lafrancol as a leader in its markets:
# 1 Pharmaceutical company in sales (including multi-nationals)1
DATA DATA

# 3 Pharmaceutical company in prescriptions2 # 1 Pharmaceutical company in new products for the last 10 years1
# 2 Pharmaceutical Company in the hormonal market1 Only Pharmaceutical Company with an Anti_TNF Biocompetitor product worldwide (except China)
DATA

DATA

Source: 1. IMS MAT_Dec_2011

2. Close_Up MAT_Dec_2011

Snapshot - Leading Manufacturers

200,000,000,000 180,000,000,000 160,000,000,000 140,000,000,000

120,000,000,000
100,000,000,000 80,000,000,000 60,000,000,000 40,000,000,000 20,000,000,000
Bayer Pharmaceutic
Glaxosmithkline

Lafrancol ranks first in sales volume (including multi-nationals), in the ethical market without milk top ten companies, with 11.92% growth, and posted the largest market gain in the industry.
Source: IMS MAT_Dec_2011

Sanofi Aventis

Boehringer Ing

0
Mckesson Lafrancol Procaps Genfar Pfizer Msd

Long-term Aggressive Growth to the Top

Ranking in IMS and Sales growth
Rank 1 19% Rank 1 Rank 1 Rank 3 22% 5% 3%

38%

41% Rank 7 Rank 13 29% 20% Rank 17 26% 3% 17% 11% 26%

Source: IMS Top Manufacturers 1999-2011 Ethical Market Without Milk / Internal Sales Data

Lafrancol Overtaking the Multinationals

Top Ten Laboratories in the Total Market Market Share %
7,00%

6,00%

5,00%

4,00%

3,00%

2,00% MTH mar/10 MTH mar/11 MTH dic/10 MTH oct/10 MTH sep/10 MTH may/10 MTH may/11 MTH ene/10 MTH ago/10 MTH ene/11 MTH ago/11 MTH sep/11 MTH abr/10 MTH abr/11 MTH feb/10 MTH feb/11 MTH nov/10 MTH oct/11 MTH jun/10 MTH jun/11 MTH nov/11 MTH dic/11 MTH jul/10 MTH jul/11

Lafrancol - (232) Msd - (91) Sanofi Aventis - (86)

Bayer Pharmaceutic - (70) Pfizer - (83) Genfar - (150)

Nestle - (17) Abbott - (60)

Glaxosmithkline - (88) Mckesson - (185)

Source: IMS December 2011

Lafrancol Absolute Market Leader

Market Share %

7,23% 6,41%

7,47% 7,06%

7,47% 7,14%

5,27%

MAT Dic/07

MAT Dic/08

MAT Dic/09

MAT Dic/10

MAT Dic/11

YTD Dic/11

MTH Dic/11

Lafrancol has shown a sustained market share gain, accompanied by higher growth in the ethical market without milk.
Source: IMS December 2011

Main Competitors MS% Ethical Market Without Milk

YTD December_11
Lafrancol 7,47%

%
11.92% 7.68% -0.61% -0.19% 1.53% 4.35% 12.92% 15.22% -4.85% 4.31%
Growth of Ethical market without milk 5.87%

Bayer Pharmaceutic

6,38%

Pfizer

5,55%

Msd

5,09%

Sanofi Aventis

4,45%

Genfar

4,24%

Mckesson

4,20%

Procaps

3,13%

Glaxosmithkline

2,83%

Boehringer Ing

2,55%

Source: IMS December 2011

THE LAFRANCOL ADVANTAGE

Advantage:
Sales & Marketing
Experienced workforce of 2,500+ employees

40% in Research and Manufacturing.

60% Sales and Marketing.

Strongest & most aggressive sales force in Colombia.

Largest medical sales force

Top selling sales force for last 10 years. Proven team as demonstrated by the most successful new product launches in the industry over the last 10 years. Aggressive operation with 45,000+ sales visits per month to physicians.

Rapid market penetration

Via successful marketing & distribution strategies.

Resulting in highest market share gains in the industry.

Advantage:
Pervasive Relationships
Physicians

Continued Medical Education and Educational University Grants

Distribution

Excellent Relationships with Wholesalers, Distributors, Private & Government Entities and Pharmacies.

Patients

Through Health Centers and Call Centers, patients are provided support on product information, adherence to therapies and medicines, how to change their nutritional habits and adhere to new habits to achieve a better quality of life.

Patient Care Programs (Cuidarte) : Focuses on assisting and educating patients using biotech
and specialty care products by assisting patients with:

At-home drug application. Patient and nurse training. Biosecurity training. Pharmacovigilance program & pharmaceutical care. Follow-up evaluations on adherence and patient satisfaction .

Advantage:
Specialized Studies
The only national pharmaceutical company with more than 30 studies in specialized areas:

Advantage:
Manufacturing
Modern plants equipped with the latest technology and providing flexible production capabilities.
o o

Cali, Colombia: 23,000 m2 modern, state-of-the-art manufacturing facility. Colombian Duty-Free Zone: 2,100 m2 manufacturing facility.

Leader in social and environmental responsibility.

Each plant operates under the most stringent quality control, as defined by international standards, including:
o o o o o

GMP (Good Manufacturing Practices for Pharmaceuticals). ISO (International Organization for Standardization) 9001. ISO (International Organization for Standardization) 28000. PIC (Pharmaceutical Inspection Convention). FDA plant compliance is currently in process.

PRODUCTS

Product Types

Injectables - Hormones
Tablets Capsules Granulates Ointments Creams Gels Syrups Sachets Powders Sterile Liquids

Product Lines

Branded Rx Generics Specialty Care: High Cost and Institutional (Private & Government) Biotech, Oncology, & HIV OTC Pharmaceuticals, Nutraceuticals and Functional Foods

Therapeutic Lines

NOTE: To view products click on image

SALES OPERATIONS

Offices in Colombia
Bogot

Corporate Medical Research Marketing Sales

Operations & Production Financial Sales & Marketing Sales Force for Physicians Health Club for Patients Health Nutritional Institute

Cali

Regional Offices

International Operations
Branch Offices and Distributors

Guatemala Peru Dominican Republic Ecuador Uruguay Belize Salvador Panama USA

Exports and Private label

Mexico Costa Rica Nicaragua Venezuela Chile

International Operations
Exports Performance
USD
14.000.000 12.000.000 10.000.000 8.000.000 6.000.000
54% 26%

Values & Growth

56%

19%

54%

4.000.000 2.000.000 0 2007 2008 2009 2010 2011

Source: Internal Data on File

INFORMATION
For more information, please contact:

CORPORATE HEADQUARTERS
Calle 108 No. 51-45, Bogot D.C. - Colombia Tel. (571) 742-2525 US OFFICE Tel. (1) 954-224-3001 Email: Lafrancol@lafrancol.com Website: www.Lafrancol.com

Therapeutic Lines

Therapeutic Lines

Therapeutic Lines

Therapeutic Lines

Therapeutic Lines

Therapeutic Lines

Therapeutic Lines

Therapeutic Lines

Therapeutic Lines

Lafrancol : Market Leader

Total Market
Sales - Total Market
(General Configuration: IMS Struct / Active to: Historical / CutOff: 10 Rows / Filters: No / )

Local Currency

Local Currency

Units

MAT dic/11 Total Selected 1 2 3 4 5 6 7 8 9 10 Lafrancol - (243) Glaxosmithkline - (104) Pfizer - (93) Bayer Pharmaceutic - (73) Msd - (99) Nestle - (17) Abbott - (65) Sanofi Aventis - (87) Mckesson - (190) Boehringer Ing - (54) Others (330) 6.1% 11.1% 15.5% 19.7% 23.9% 27.8% 31.6% 35.3% 38.7% 41.6%

MAT dic/11 244,691,755,462 198,981,237,527 175,138,272,715 169,561,079,791 164,220,469,542 157,160,826,861 151,883,692,303 149,788,666,968 132,223,018,131 117,870,674,910

MTH dic/11 21,325,479,938 15,791,894,250 15,315,026,876 18,842,510,839 15,342,459,853 15,900,248,974 14,292,667,004 12,831,109,940 13,226,631,898 10,250,202,520

MAT dic/11 MTH dic/11 24,520,108 15,403,599 5,152,909 7,642,966 7,369,966 9,893,256 9,280,479 5,581,281 22,231,407 8,213,799 2,007,286 1,230,079 431,994 1,013,321 756,727 986,461 881,599 490,891 2,206,092 689,827

Accumulated 3,992,954,038,423 365,775,183,353 328,289,091 29,893,534

100.0% 2,331,434,344,213 212,656,951,261 212,999,321 19,199,257

Performans - Etika -

Source: IMS Colombia (dic/2012)

Source: IMS MAT_Dec_11

Lafrancol : Hormonal Market

Segment Analysis
Sales - G
(General Configuration: IMS Struct / Active to: Historical / CutOff: 10 Rows / Filters: No / ) Local Currency Local Currency Units

MTH dic/11 Total Selected 1 2 3 4 5 6 7 8 9 10 Bayer Pharmaceutic - (30) Lafrancol - (31) Pfizer - (14) Sanofi Aventis - (8) Boehringer Ing - (5) Gynopharm - (16) Profamilia - (9) Lilly - (2) Tecnofarma - (8) Bayer Consume Care - (2) Others (95) 30.6% 46.8% 51.2% 55.6% 59.8% 63.7% 67.3% 70.1% 72.1% 74.1%

MAT dic/11 92,434,124,903 70,215,787,546 20,145,343,167 21,692,234,350 19,803,995,130 15,667,995,808 17,270,354,487 11,693,206,576 8,812,067,156 8,819,688,802

MTH dic/11 12,038,935,449 6,355,843,398 1,730,375,162 1,706,986,815 1,674,235,513 1,515,141,064 1,405,539,744 1,133,078,350 784,337,737 781,050,720

MAT dic/11 MTH dic/11 31,011,598 4,761,064 6,651,239 1,000,892 1,107,910 885,946 794,234 1,483,500 192,844 135,659 565,746 13,432,564 3,008,393 732,663 591,501 78,084 92,839 68,554 65,787 120,582 18,064 12,084 48,386 1,179,849

Accumulated 398,709,673,120 39,294,770,911

100.0% 112,154,875,195 10,169,246,959

Performans - Etika -

Source: IMS Colombia (dic/2012) Source: IMS MAT_Dec_11

Lafrancol : New Products

Source: IMS Colombia Dec_11

Lafrancol : Prescriptions

Source: Close_Up YTD_Dec_11

Advantage:
Special Studies

American College of Rheumathology, Atlanta 2.010 APLAR, Taiwan 2.011 EULAR. Londres 2.011

Advantage:
Special Studies

Advantage:
Special Studies

Advantage:
Special Studies